[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1203937A1 - Phenoxyethyl piperidine compounds - Google Patents

Phenoxyethyl piperidine compounds

Info

Publication number
HK1203937A1
HK1203937A1 HK15104361.6A HK15104361A HK1203937A1 HK 1203937 A1 HK1203937 A1 HK 1203937A1 HK 15104361 A HK15104361 A HK 15104361A HK 1203937 A1 HK1203937 A1 HK 1203937A1
Authority
HK
Hong Kong
Prior art keywords
piperidine compounds
phenoxyethyl
phenoxyethyl piperidine
compounds
piperidine
Prior art date
Application number
HK15104361.6A
Other languages
English (en)
Chinese (zh)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1203937A1 publication Critical patent/HK1203937A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104361.6A 2012-06-29 2015-05-07 Phenoxyethyl piperidine compounds HK1203937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
HK1203937A1 true HK1203937A1 (en) 2015-11-06

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104361.6A HK1203937A1 (en) 2012-06-29 2015-05-07 Phenoxyethyl piperidine compounds

Country Status (43)

Country Link
US (2) US8962659B2 (uk)
EP (1) EP2867207B1 (uk)
JP (1) JP6127136B2 (uk)
KR (1) KR101653476B1 (uk)
CN (1) CN104411684B (uk)
AP (1) AP2014008164A0 (uk)
AR (1) AR091429A1 (uk)
AU (1) AU2013280875B2 (uk)
BR (1) BR112014031616B1 (uk)
CA (1) CA2875569C (uk)
CL (1) CL2014003535A1 (uk)
CO (1) CO7151507A2 (uk)
CR (1) CR20140553A (uk)
CY (1) CY1119425T1 (uk)
DK (1) DK2867207T3 (uk)
DO (1) DOP2014000287A (uk)
EA (1) EA024392B1 (uk)
EC (1) ECSP14033267A (uk)
ES (1) ES2644812T3 (uk)
GT (1) GT201400288A (uk)
HK (1) HK1203937A1 (uk)
HR (1) HRP20171515T1 (uk)
HU (1) HUE034425T2 (uk)
IL (1) IL236219A (uk)
JO (1) JO3296B1 (uk)
LT (1) LT2867207T (uk)
MA (1) MA37686B1 (uk)
ME (1) ME02840B (uk)
MX (1) MX345324B (uk)
MY (1) MY173878A (uk)
NZ (1) NZ701933A (uk)
PE (1) PE20150182A1 (uk)
PH (1) PH12015500009A1 (uk)
PL (1) PL2867207T3 (uk)
PT (1) PT2867207T (uk)
RS (1) RS56452B1 (uk)
SG (1) SG11201408641UA (uk)
SI (1) SI2867207T1 (uk)
TN (1) TN2014000501A1 (uk)
TW (1) TWI599561B (uk)
UA (1) UA114325C2 (uk)
WO (1) WO2014004229A1 (uk)
ZA (1) ZA201408632B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
US9776964B2 (en) * 2013-12-17 2017-10-03 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
RS62398B1 (sr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
SI3625222T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati fenila kot modulatorji receptorja pge2
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
CA3126484A1 (en) * 2019-01-22 2020-07-30 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
AU2004268839A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
AP2006003785A0 (en) * 2004-05-04 2006-10-31 Pfizer Substituted methylaryl or heteroaryl amide compounds
DE602005015215D1 (de) 2004-05-04 2009-08-13 Raqualia Pharma Inc Orthosubstituierte aryl- oder heteroarylamidverbindungen
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN102770159A (zh) 2010-02-22 2012-11-07 拉夸里亚创药株式会社 Ep-4受体拮抗剂在治疗il-23介导疾病中的用途
LT2619182T (lt) * 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Also Published As

Publication number Publication date
NZ701933A (en) 2017-01-27
AU2013280875A1 (en) 2014-12-04
TW201412717A (zh) 2014-04-01
PL2867207T3 (pl) 2018-01-31
EP2867207B1 (en) 2017-08-09
CN104411684B (zh) 2016-08-24
HRP20171515T1 (hr) 2017-11-17
PE20150182A1 (es) 2015-02-13
AU2013280875B2 (en) 2015-09-24
JP2015522018A (ja) 2015-08-03
WO2014004229A1 (en) 2014-01-03
DK2867207T3 (en) 2017-09-11
US8962659B2 (en) 2015-02-24
EA201492255A1 (ru) 2015-03-31
BR112014031616B1 (pt) 2022-06-21
BR112014031616A2 (pt) 2017-06-27
GT201400288A (es) 2015-08-27
MX2014015953A (es) 2015-07-17
CR20140553A (es) 2015-02-04
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
US20150126555A1 (en) 2015-05-07
CY1119425T1 (el) 2018-03-07
AP2014008164A0 (en) 2014-12-31
PH12015500009B1 (en) 2015-03-02
EA024392B1 (ru) 2016-09-30
MA37686A1 (fr) 2016-09-30
MA37686B1 (fr) 2017-04-28
TWI599561B (zh) 2017-09-21
ES2644812T3 (es) 2017-11-30
AR091429A1 (es) 2015-02-04
SG11201408641UA (en) 2015-01-29
JP6127136B2 (ja) 2017-05-10
US20140005226A1 (en) 2014-01-02
HUE034425T2 (en) 2018-02-28
ZA201408632B (en) 2017-06-28
CO7151507A2 (es) 2014-12-29
PH12015500009A1 (en) 2015-03-02
TN2014000501A1 (en) 2016-03-30
CL2014003535A1 (es) 2015-05-08
EP2867207A1 (en) 2015-05-06
CA2875569A1 (en) 2014-01-03
RS56452B1 (sr) 2018-01-31
JO3296B1 (ar) 2018-09-16
LT2867207T (lt) 2017-10-10
SI2867207T1 (sl) 2017-10-30
IL236219A (en) 2017-12-31
MY173878A (en) 2020-02-26
ME02840B (me) 2018-01-20
UA114325C2 (uk) 2017-05-25
KR20150013893A (ko) 2015-02-05
US9402838B2 (en) 2016-08-02
MX345324B (es) 2017-01-25
KR101653476B1 (ko) 2016-09-01
PT2867207T (pt) 2017-11-01
IL236219A0 (en) 2015-02-01
DOP2014000287A (es) 2015-01-31
CA2875569C (en) 2016-04-19

Similar Documents

Publication Publication Date Title
HRP20181889T1 (hr) Spojevi tetrahidropirazolopirimidina
HK1245780B (zh) 咪唑並吡咯烷酮化合物
EP2925129A4 (en) PRO-NEUROGENIC COMPOUNDS
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
HK1206726A1 (en) Imidazotriazinone compounds
HK1203937A1 (en) Phenoxyethyl piperidine compounds
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1211283A1 (en) Compounds
GB201209096D0 (en) Compounds
HK1206356A1 (en) Lpar - substituted cyanopyrazole compounds lpar-
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218774D0 (en) Compounds
GB201218018D0 (en) Compounds
GB201217311D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210617